Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lenalidomide is a structural analogue of thalidomide with similar but more potent biologic activity. This phase 3, placebo-controlled trial investigated the efficacy of lenalidomide plus dexamethasone in the treatment of relapsed or refractory multiple myeloma. METHODS: Of 351 patients who had received at least one previous antimyeloma therapy, 176 were randomly assigned to receive 25 mg of oral lenalidomide and 175 to receive placebo on days 1 to 21 of a 28-day cycle. In addition, all patients received 40 mg of oral dexamethasone on days 1 to 4, 9 to 12, and 17 to 20 for the first four cycles and subsequently, after the fourth cycle, only on days 1 to 4. Patients continued in the study until the occurrence of disease progression or unacceptable toxic effects. The primary end point was time to progression. RESULTS: The time to progression was significantly longer in the patients who received lenalidomide plus dexamethasone (lenalidomide group) than in those who received placebo plus dexamethasone (placebo group) (median, 11.3 months vs. 4.7 months; P<0.001). A complete or partial response occurred in 106 patients in the lenalidomide group (60.2%) and in 42 patients in the placebo group (24.0%, P<0.001), with a complete response in 15.9% and 3.4% of patients, respectively (P<0.001). Overall survival was significantly improved in the lenalidomide group (hazard ratio for death, 0.66; P=0.03). Grade 3 or 4 adverse events that occurred in more than 10% of patients in the lenalidomide group were neutropenia (29.5%, vs. 2.3% in the placebo group), thrombocytopenia (11.4% vs. 5.7%), and venous thromboembolism (11.4% vs. 4.6%). CONCLUSIONS: Lenalidomide plus dexamethasone is more effective than high-dose dexamethasone alone in relapsed or refractory multiple myeloma. (ClinicalTrials.gov number, NCT00424047 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [31]
In the citing paper
“(iv) they are already a therapeutic reality.[56][57][58][59][60][61][62][63][64][65][66][67]”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [57]
In the citing paper
“A randomized study comparing lenalidomide and dexamethasone to melphalan, thalidomide and prednisone in newly diagnosed patients demonstrated superior 4-year OS (59% versus 51%; HR 0.78, p=0.02) and led to FDA approval in 201527.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [27]
In the citing paper
“For older patients and/or those unfit for autologous transplantation, the preferred induction approach remains lenalidomide in combination with dexamethasone with or without daratumumab, regimens that are effective and well tolerated in this patient population27,29.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [27]
In the citing paper
“Thalidomide analogues often lead to peripheral blood cytopenias, most commonly neutropenia (28% grade 3/4) and thrombocytopenia (8% grade 3/4)27.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [27]
Citations
Cites
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Self-citationBladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Cancer incidence and mortality in Europe, 2004
Boyle, P., & Ferlay, J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi098 · Cited by 1,217
Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y.-T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 875
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Self-citationRichardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015909 · Cited by 523
Self-citationCombination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma
Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.116 · Cited by 512
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
Hideshima, T., & Anderson, K. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc952 · Cited by 425
Thalidomide and dexamethasone combination for refractory multiple myeloma
Dimopoulos, M. A., Zervas, K., Kouvatseas, G., Galani, E., Grigoraki, V., Kiamouris, C., Vervessou, E., Samantas, E., Papadimitriou, C., Economou, O., et al. (2001) · Annals of Oncology · doi:10.1023/a:1011132808904 · Cited by 283
Self-citationGarcía-Sanz, R., González-Porras, J. R., Hernández, J. M., Polo-Zarzuela, M., Sureda, A., Barrenetxea, C., Palomera, L., López, R., Grande-García, C., Alegre, A., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403322 · Cited by 159
Self-citation
Cited by
Items 101–200 of 1,000
Giralt, S., Garderet, L., Durie, B., Cook, G., Gahrton, G., Bruno, B., Hari, P., Lokhorst, H., McCarthy, P., Krishnan, A., et al. (2015) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2015.09.016 · Cited by 165
“Len/Dex [16-18] 60.”
Self-citationMartin, T., Baz, R., Benson, D. M., Lendvai, N., Wolf, J., Munster, P., Lesokhin, A. M., Wack, C., Charpentier, E., Campana, F., et al. (2017) · Blood · doi:10.1182/blood-2016-09-740787 · Cited by 166
Popat, U., Saliba, R., Thandi, R., Hosing, C., Qazilbash, M., Anderlini, P., Shpall, E., McMannis, J., Körbling, M., Alousi, A., et al. (2009) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2009.02.011 · Cited by 169
“5 (38–76) Sex Men 185 (61) Women 117 (39) Isotype IgG 177 (59) IgA 63 (21) Light chain only 47 (15) Other (IgD, IgM, Nonsecretory) 15 (5) Durie-Salmon stage at diagnosis I 59 (20) II 127 (42) III 103 (34) Unknown 13 (4) No.”
Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion
Neri, P., Ren, L., Azab, A. K., Brentnall, M., Gratton, K., Klimowicz, A. C., Lin, C., Duggan, P., Tassone, P., Mansoor, A., et al. (2011) · Blood · doi:10.1182/blood-2010-06-292243 · Cited by 162
“21 In sum, these results along with our findings suggest that (1) 7-integrin is responsible for MM-cell adhesion to E-CDH and (2) MM-cell adhesion to FN and BMSCs is dependent on several integrins ( 4 1, 5 1, etc) including 7 ( 4 7, E 7).”
ResultHarousseau, J.-L., Avet-Loiseau, H., Attal, M., Charbonnel, C., Garban, F., Hulin, C., Michallet, M., Facon, T., Garderet, L., Marit, G., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1060 · Cited by 164
Self-citationRichardson, P. G., Weller, E., Jagannath, S., Avigan, D. E., Alsina, M., Schlossman, R. L., Mazumder, A., Munshi, N. C., Ghobrial, I. M., Doss, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.2679 · Cited by 162
“Overall response rate (ie, CR nCR PR MR) 61% (90% CI, 46% to 75%) per modified European Group for Blood and Marrow Transplantation criteria.(4) Lenalidomide Plus Bortezomib in Relapsed/Refractory Myeloma”
BackgroundSelf-citationAssociation of response endpoints with survival outcomes in multiple myeloma
Lonial, S., & Anderson, K. C. (2014) · Leukemia · doi:10.1038/leu.2013.220 · Cited by 162
Lenalidomide enhances anti-myeloma cellular immunity
Luptakova, K., Rosenblatt, J., Glotzbecker, B., Mills, H., Stroopinsky, D., Kufe, T., Vasir, B., Arnason, J., Tzachanis, D., Zwicker, J. I., et al. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1308-3 · Cited by 162
Katritzky, A. R., Hall, C. D., El-Gendy, B. E.-D. M., & Draghici, B. (2010) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-010-9359-z · Cited by 161
Baz, R. C., Martin, T. G., Lin, H.-Y., Zhao, X., Shain, K. H., Cho, H. J., Wolf, J. L., Mahindra, A., Chari, A., Sullivan, D. M., et al. (2016) · Blood · doi:10.1182/blood-2015-11-682518 · Cited by 159
Emerging immunotherapies in multiple myeloma
Shah, U. A., & Mailankody, S. (2020) · BMJ · doi:10.1136/bmj.m3176 · Cited by 154
Ocio, E. M., Vilanova, D., Atadja, P., Maiso, P., Crusoe, E., Fernandez-Lazaro, D., Garayoa, M., San-Segundo, L., Hernandez-Iglesias, T., de Alava, E., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.015495 · Cited by 157
“On this background we report on the anti-MM activity of the combination of panobinostat, a novel deacetylase inhibitor, with dexamethasone and either one of two recently approved drugs with well established anti-MM action: the proteasome inhibitor bortezomib 20,21 and the immunomodulatory drug lenalidomide.(22,23) As…”
BackgroundSelf-citationRichardson, P., Jagannath, S., Hussein, M., Berenson, J., Singhal, S., Irwin, D., Williams, S. F., Bensinger, W., Badros, A. Z., Vescio, R., et al. (2009) · Blood · doi:10.1182/blood-2008-12-196238 · Cited by 158
“17 Duration of response was measured from the time of best response (Ն PR or Ն MR) to progression of disease, including death due to MM. TTP was estimated as the time from the start of lenalidomide treatment to the first occurrence of any of the following events: disease progression with TTP measured at the date of th…”
BackgroundInfluentialSelf-citationHsu, A. K., Quach, H., Tai, T., Prince, H. M., Harrison, S. J., Trapani, J. A., Smyth, M. J., Neeson, P., & Ritchie, D. S. (2011) · Blood · doi:10.1182/blood-2010-04-278432 · Cited by 158
Self-citationMultiple myeloma: 2013 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2013) · American Journal of Hematology · doi:10.1002/ajh.23390 · Cited by 159
Treatment options for relapsed and refractory multiple myeloma
Nooka, A. K., Kastritis, E., Dimopoulos, M. A., & Lonial, S. (2015) · Blood · doi:10.1182/blood-2014-11-568923 · Cited by 158
Self-citationRichardson, P. G. G., Jagannath, S., Moreau, P., Jakubowiak, A. J., Raab, M. S., Facon, T. T. F., Vij, R., White, D. J., Reece, D. E., Benboubker, L., et al. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00197-0 · Cited by 163
Self-citationThe bone-marrow niche in MDS and MGUS: implications for AML and MM
Ghobrial, I. M., Detappe, A., Anderson, K. C., & Steensma, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.197 · Cited by 171
Quintás-Cardama, A., Kantarjian, H. M., Manshouri, T., Thomas, D., Cortes, J., Ravandi, F., Garcia-Manero, G., Ferrajoli, A., Bueso-Ramos, C., & Verstovsek, S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6548 · Cited by 155
Treatment of Multiple Myeloma: A Comprehensive Review
Kyle, R. A., & Rajkumar, S. V. (2009) · Clinical Lymphoma and Myeloma · doi:10.3816/clm.2009.n.056 · Cited by 151
Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2011) · American Journal of Hematology · doi:10.1002/ajh.21913 · Cited by 152
Improved long-term survival in multiple myeloma up to the age of 80 years
Kristinsson, S. Y., Anderson, W. F., & Landgren, O. (2014) · Leukemia · doi:10.1038/leu.2014.23 · Cited by 157
Pulte, D., Gondos, A., & Brenner, H. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0229 · Cited by 144
“Several unconventional agents, including the immunomodulators thalidomide [3] and lenalidomide [15] and the proteosome inhibitor bortezomib [4], have been shown to produce longer survival times in patients with MM in clinical trials.”
BackgroundRichardson, P. G. G., Mitsiades, C. S., Laubach, J. P., Lonial, S., Chanan-Khan, A. A., & Anderson, K. C. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08360.x · Cited by 157
Dimopoulos, M. A., Richardson, P. G., Brandenburg, N., Yu, Z., Weber, D. M., Niesvizky, R., & Morgan, G. J. (2012) · Blood · doi:10.1182/blood-2011-08-373514 · Cited by 148
Self-citationPalumbo, A. P., Sezer, O., Kyle, R. A., Miguel, J. F. S., Orlowski, R. Z., Moreau, P., Niesvizky, R., Morgan, G. J., Comenzo, R. L., Sonneveld, P., et al. (2009) · Leukemia · doi:10.1038/leu.2009.122 · Cited by 166
Self-citationBortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
Robak, P. J., & Robak, T. (2019) · Drugs in R&D · doi:10.1007/s40268-019-0269-9 · Cited by 152
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis
Barwick, B. G., Neri, P., Bahlis, N. J., Nooka, A. K., Dhodapkar, M. V., Jaye, D. L., Hofmeister, C. C., Kaufman, J. L., Gupta, V. A., Auclair, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09555-6 · Cited by 146
Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2012) · American Journal of Hematology · doi:10.1002/ajh.22237 · Cited by 144
Multiple myeloma: the (r)evolution of current therapy and a glance into future
Gullà, A., & Anderson, K. C. (2020) · Haematologica · doi:10.3324/haematol.2020.247015 · Cited by 154
Therapy for Relapsed Multiple Myeloma
Dingli, D., Ailawadhi, S., Bergsagel, P. L., Buadi, F. K., Dispenzieri, A., Fonseca, R., Gertz, M. A., Gonsalves, W. I., Hayman, S. R., Kapoor, P., et al. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.01.003 · Cited by 140
de la Puente, P., Muz, B., Gilson, R. C., Azab, F., Luderer, M. J., King, J. A., Achilefu, S., Vij, R., & Azab, A. K. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.09.017 · Cited by 152
“Despite the introduction of several novel drugs and their high efficacy in vitro, only about 60% of patients initially respond to therapy, and among relapsed patients more than 90% develop drug resistance [3-6].”
San-Miguel, J. F., Richardson, P. G., Günther, A., Sezer, O., Siegel, D., Bladé, J., LeBlanc, R., Sutherland, H., Sopala, M., Mishra, K. K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.7068 · Cited by 139
Self-citationLaubach, J., Richardson, P., & Anderson, K. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-070209-175325 · Cited by 139
Avet‐Loiseau, H., Soulier, J., Fermand, J., Yakoub‐Agha, I., Attal, M., Hulin, C., Garderet, L., Belhadj, K., Dorvaux, V., Minvielle, S., et al. (2010) · Leukemia · doi:10.1038/leu.2009.273 · Cited by 138
Self-citationApproach to the treatment of multiple myeloma: a clash of philosophies
Rajkumar, S. V., Gahrton, G., & Bergsagel, P. L. (2011) · Blood · doi:10.1182/blood-2011-06-297853 · Cited by 137
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137
Lee, S. M., Woll, P. J., Rudd, R., Ferry, D. R., O'Brien, M. E. R., Middleton, G., Spiro, S. G., James, L. E., Ali, K., Jitlal, M., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp200 · Cited by 136
Ravi, P. K., Kumar, S. K., Cerhan, J. R., Maurer, M. J., Dingli, D., Ansell, S. M., & Rajkumar, S. V. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0065-8 · Cited by 142
Avet-Loiseau, H., Ludwig, H., Landgren, O., Paiva, B., Morris, C., Yang, H., Zhou, K., Ro, S., & Mateos, M.-V. (2020) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2019.09.622 · Cited by 134
Broyl, A., Kuiper, R., van Duin, M., van der Holt, B., el Jarari, L., Bertsch, U., Zweegman, S., Buijs, A., Hose, D., Lokhorst, H. M., et al. (2013) · Blood · doi:10.1182/blood-2012-06-438101 · Cited by 130
Dimopoulos, M. A., Alegre, A. M., Stadtmauer, E. A., Goldschmidt, H., Zonder, J. A., de Castro, C. M., Masliak, Z., Reece, D. E., Olesnyckyj, M., Yu, Z., et al. (2010) · Cancer · doi:10.1002/cncr.25139 · Cited by 137
Self-citationBjorklund, C. C., Baladandayuthapani, V, Lin, H. Y., Jones, R. J., Kuiatse, I., Wang, H., Yang, J., Shah, J. J., Thomas, S. K., Wang, M., et al. (2014) · Leukemia · doi:10.1038/leu.2013.174 · Cited by 131
Jordan, K., Proskorovsky, I., Lewis, P., Ishak, J., Payne, K. A., Lordan, N. D., Kyriakou, C. A., Williams, C. D., Peters, S., & Davies, F. E. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-013-1991-4 · Cited by 137
Bjorklund, C. C., Ma, W., Wang, Z.-Q., Davis, R. E., Kuhn, D. J., Kornblau, S. M., Wang, M., Shah, J. J., & Orlowski, R. Z. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.180208 · Cited by 130
Anderson, K. C. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.8919 · Cited by 129
Continued survival gains in recent years among critically ill myeloma patients
Peigne, V., Rusínová, K., Karlin, L., Darmon, M., Fermand, J., Schlemmer, B., & Azoulay, É. (2008) · Intensive Care Medicine · doi:10.1007/s00134-008-1320-4 · Cited by 129
“, bortezomib and lenalidomide) can induce serious side effects [3, 5, 6, 9, 10].”
BackgroundMoreau, P., Jaccard, A., Benboubker, L., Royer, B., Leleu, X. P., Bridoux, F., Salles, G. A., Leblond, V., Roussel, M., Alakl, M., et al. (2010) · Blood · doi:10.1182/blood-2010-07-294405 · Cited by 129
Self-citationHeintel, D., Rocci, A., Ludwig, H., Bolomsky, A., Caltagirone, S., Schreder, M., Pfeifer, S., Gisslinger, H., Zojer, N., Jäger, U., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12338 · Cited by 128
“The immunomodulatory drugs (IMiDs), thalidomide, lenalidomide and pomalidomide exert significant activity in the treatment of multiple myeloma (MM) (Singhal et al, 1999; Dimopoulos et al, 2007, 2009; Van Rhee et al, 2008; Galustian & Dalgleish, 2009; Lacy, 2011; Schey & Ramasamy, 2011).”
BackgroundWang, M., Martin, T., Bensinger, W., Alsina, M., Siegel, D. S., Kavalerchik, E., Huang, M., Orlowski, R. Z., & Niesvizky, R. (2013) · Blood · doi:10.1182/blood-2013-07-511170 · Cited by 129
Kaufman, J. L., Niesvizky, R., Stadtmauer, E. A., Chanan‐Khan, A., Siegel, D., Horne, H., Wegener, W. A., & Goldenberg, D. M. (2013) · British Journal of Haematology · doi:10.1111/bjh.12565 · Cited by 125
“…25 September 2013 doi: 10.1111/bjh.12565 ª 2013 John Wiley & Sons Ltd British Journal of Haematology, 2013, 163, 478–486 and pegylated liposomal doxorubicin (Richardson et al, 2005; Rajkumar et al, 2006; Dimopoulos et al, 2007; Orlowski et al, 2007; Weber et al, 2007; San Miguel et al, 2008).”
BackgroundInfluentialTreatment Options for Relapsed and Refractory Multiple Myeloma
Lonial, S., Mitsiades, C. S., & Richardson, P. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1805 · Cited by 127
Pathway network of pyroptosis and its potential inhibitors in acute kidney injury
Li, N., Wang, Y., Wang, X., Sun, N., & Gong, Y.-H. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106033 · Cited by 131
Dimopoulos, M. A., Leleu, X. P., Palumbo, A. P., Moreau, P., Delforge, M., Cavo, M., Ludwig, H., Morgan, G. J., Davies, F. E., Sonneveld, P., et al. (2014) · Leukemia · doi:10.1038/leu.2014.60 · Cited by 127
Self-citationGay, F., Hayman, S. R., Lacy, M. Q., Buadi, F., Gertz, M. A., Kumar, S., Dispenzieri, A., Mikhael, J. R., Bergsagel, P. L., Dingli, D., et al. (2010) · Blood · doi:10.1182/blood-2009-08-239046 · Cited by 124
“Lenalidomide (CC-5013), an analogue of thalidomide, is more potent in preclinical assays than thalidomide(9,10) and has fewer non-hematologic side-effects compared to the parent drug.(11,12) In newly diagnosed patients, lenalidomide plus high-dose dexamethasone was”
Backgroundvan Beurden-Tan, C. H. Y., Franken, M. G., Blommestein, H. M., Groot, C. A. U., & Sonneveld, P. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.1663 · Cited by 132
Molecular mechanisms of thalidomide and its derivatives
Ito, T., & Handa, H. (2020) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.96.016 · Cited by 134
Zinzani, P. L., Vose, J. M., Czuczman, M. S., Reeder, C. B., Haïoun, C., Polikoff, J. A., Tilly, H., Zhang, L. F., Prandi, K., Li, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt366 · Cited by 122
“data are consistent with the low incidence of clinical problems secondary to cytopenia in relapsed/refractory multiple myeloma patients treated with lenalidomide/dexamethasone [15, 16].”
ResultLenalidomide mode of action: linking bench and clinical findings
Davies, F. E., & Baz, R. (2010) · Blood Reviews · doi:10.1016/s0268-960x(10)70004-7 · Cited by 123
Jagannath, S., Vij, R., Stewart, A. K., Trudel, S., Jakubowiak, A. J., Reiman, T., Somlo, G., Bahlis, N. J., Lonial, S., Kunkel, L., et al. (2012) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2012.08.003 · Cited by 124
“Number of Previous Treatments, Median (Range) 5 (2-16)”
BackgroundChemotherapy-induced peripheral neuropathy: an update on the current understanding
Addington, J., & Freimer, M. L. (2016) · F1000Research · doi:10.12688/f1000research.8053.1 · Cited by 136
Dimopoulos, M. A., Kastritis, E., Christoulas, D., Migkou, M., Gavriatopoulou, M., Gkotzamanidou, M. A., Iakovaki, M., Matsouka, C., Mparmparoussi, D., Ρούσσου, Μ., et al. (2010) · Leukemia · doi:10.1038/leu.2010.175 · Cited by 125
Self-citationVenous thromboembolism incidence in hematologic malignancies
Kekre, N. K., & Connors, J. M. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.06.002 · Cited by 127
Lentzsch, S., O'Sullivan, A., Kennedy, R. C., Abbas, M., Dai, L., Pregja, S. L., Burt, S., Boyiadzis, M., Roodman, G. D., Mapara, M. Y., et al. (2012) · Blood · doi:10.1182/blood-2011-12-395715 · Cited by 119
Knop, S., Gerecke, C., Liebisch, P., Topp, M. S., Platzbecker, U., Sezer, O., Vollmuth, C., Falk, K., Glasmacher, A., Maeder, U., et al. (2009) · Blood · doi:10.1182/blood-2008-10-184135 · Cited by 120
Thrombosis in Multiple Myeloma
Kristinsson, S. Y. (2010) · Hematology · doi:10.1182/asheducation-2010.1.437 · Cited by 128
Thrombosis associated with angiogenesis inhibitors
Elice, F., Rodeghiero, F., Falanga, A., & Rickles, F. R. (2009) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2009.01.001 · Cited by 123
Mark, T., Stern, J., Furst, J. R., Jayabalan, D., Zafar, F., LaRow, A., Pearse, R. N., Harpel, J., Shore, T., Schuster, M. W., et al. (2008) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2008.04.008 · Cited by 117
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
Dimopoulos, M. A., Palumbo, A. P., Attal, M., Beksaç, M., Davies, F. E., Delforge, M., Einsele, H., Hájek, R., Harousseau, J., da Costa, F. L., et al. (2011) · Leukemia · doi:10.1038/leu.2011.3 · Cited by 118
Self-citationKidney dysfunction during lenalidomide treatment for AL amyloidosis
Specter, R., Sanchorawala, V., Seldin, D. C., Shelton, A. C., Fennessey, S. A., Finn, K. T., Zeldis, J. B., & Dember, L. M. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq482 · Cited by 115
“Lenalidomide is an immunomodulatory agent that was initially developed as a treatment for multiple myeloma [9–13].”
BackgroundSelf-citationHarousseau, J., Dimopoulos, M. A., Wang, M., Corso, A., Chen, C. L., Attal, M., Spencer, A., Yu, Z., Olesnyckyj, M., Zeldis, J. B., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.015917 · Cited by 116
“The protocols of these two studies were described in detail in the primary publications.(9,10) When the predetermined O’Brien–”
MethodResultSelf-citationMultiple myeloma: practice patterns across Europe
Raab, M. S., Cavo, M., Delforge, M., Driessen, C., Fink, L., Flinois, A., Gonzalez‐McQuire, S., Safaei, R., Karlin, L., Mateos, M., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14193 · Cited by 112
“This is perhaps surprising given the activity of bortezomib and lenalidomide in second- and third-line settings (Richardson et al, 2005, 2007; Dimopoulos et al, 2007; Weber et al, 2007) and the availability of bendamustine and pomalidomide for patients refractory to these agents.”
Resistance to proteasome inhibitors and other targeted therapies in myeloma
Wallington-Beddoe, C. T., Sobieraj‐Teague, M., Kuss, B. J., & Pitson, S. M. (2018) · British Journal of Haematology · doi:10.1111/bjh.15210 · Cited by 116
Outcome disparities in multiple myeloma: a SEER ‐based comparative analysis of ethnic subgroups
Ailawadhi, S., Aldoss, I. T., Yang, D., Razavi, P., Cozen, W., Sher, T., & Chanan-Khan, A. A. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09124.x · Cited by 124
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma
Plesner, T., Arkenau, H.-T., Gimsing, P., Krejcik, J., Lemech, C., Minnema, M. C., Lassen, U., Laubach, J. P., Palumbo, A., Lisby, S., et al. (2016) · Blood · doi:10.1182/blood-2016-07-726729 · Cited by 109
Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias
Eby, C. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07577.x · Cited by 114
A phase-2 trial of low-dose pomalidomide in myelofibrosis
Begna, K. H., Mesa, R. A., Pardanani, A. D., Hogan, W. J., Litzow, M. R., McClure, R. F., & Tefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.254 · Cited by 112
Management of multiple myeloma in the relapsed/refractory patient
Sonneveld, P. (2017) · Hematology · doi:10.1182/asheducation-2017.1.508 · Cited by 107
Review of health-related quality of life data in multiple myeloma patients treated with novel agents
Sonneveld, P., Verelst, S. G. R., Lewis, P., Gray‐Schopfer, V. C., Hutchings, A., Nixon, A., & Petrucci, M. T. (2013) · Leukemia · doi:10.1038/leu.2013.185 · Cited by 113
Fiber Based Approaches as Medicine Delivery Systems
Sharifi, F. J., Sooriyarachchi, A., Altural, H., Montazami, R., Rylander, M. N., & Hashemi, N. N. (2016) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.6b00281 · Cited by 116
Management of cardiovascular risk in patients with multiple myeloma
Plummer, C., Driessen, C., Szabó, Z. R., & Mateos, M. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0183-y · Cited by 115
Ishikawa, T., Okayama, T., Sakamoto, N., Ideno, M., Oka, K., Enoki, T., Mineno, J., Yoshida, N., Katada, K., Kamada, K., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31285 · Cited by 108
Stadtmauer, E. A., Weber, D. M., Niesvizky, R., Belch, A., Prince, M. H., Miguel, J. F. S., Facon, T. T. F., Olesnyckyj, M., Yu, Z., Zeldis, J. B., et al. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01257.x · Cited by 114
“The MM-009 and MM-010 trials were initiated on 27 February 2003, and 22 September 2003, respectively.”
BackgroundMethodInfluentialSelf-citationExtramedullary multiple myeloma
Weinstock, M., & Ghobrial, I. M. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.740562 · Cited by 118
Lioznov, M. V., Cheikh, J. E., Hoffmann, F. A., Hildebrandt, Y., Ayuk, F. A., Wolschke, C., Atanackovic, D., Schilling, G., Badbaran, A., Bacher, U., et al. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.155 · Cited by 104
Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review
Li, W., Garcia, D. A., Cornell, R. F., Gailani, D., Laubach, J. P., Maglio, M. E., Richardson, P. G. G., & Moslehi, J. J. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3350 · Cited by 109
Cornell, R. F., & Kassim, A. A. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.307 · Cited by 100
Warren, J. L., Harlan, L. C., Stevens, J. L., Little, R. F., & Abel, G. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3323 · Cited by 102
Minnema, M. C., van der Veer, M. S., Aarts‐Riemens, T., Emmelot, M. E., Mutis, T., & Lokhorst, H. M. (2008) · Leukemia · doi:10.1038/leu.2008.247 · Cited by 104
“dtd"[ ]> Lenalidomide has demonstrated significant clinical activity in patients with newly diagnosed and relapsed multiple myeloma (MM)”
NF-??B in the pathogenesis and treatment of multiple myeloma
Li, Z.-W., Chen, H., Campbell, R. A., Bonavida, B., & Berenson, J. R. (2008) · Current Opinion in Hematology · doi:10.1097/moh.0b013e328302c7f4 · Cited by 93
Bruno, B., Rotta, M., Patriarca, F. F., Mattei, D. G., Allione, B., Carnevale‐Schianca, F., Sorasio, R., Rambaldi, A., Casini, M., Parma, M., et al. (2008) · Blood · doi:10.1182/blood-2008-07-167379 · Cited by 100
Turning liabilities into opportunities: Off-target based drug repurposing in cancer
Palve, V. C., Liao, Y., Rix, L. L. R., & Rix, U. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.003 · Cited by 103
Novel immunomodulatory drugs and neo-substrates
Gao, S., Wang, S., & Song, Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-0182-y · Cited by 95
Papadopoulos, K. P., Siegel, D. S. D., Vesole, D. H., Lee, P., Rosen, S. T., Zojwalla, N. J., Holahan, J. R., Lee, S., Wang, Z., & Badros, A. Z. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.3522 · Cited by 96
Li, S., Pal, R., Monaghan, S. A., Schafer, P., Ouyang, H., Mapara, M., Galson, D. L., & Lentzsch, S. (2011) · Blood · doi:10.1182/blood-2010-10-314278 · Cited by 94
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
Ludwig, H., Beksaç, M., Bladé, J., Boccadoro, M., Cavenagh, J. D., Cavo, M., Dimopoulos, M. A., Drach, J. W., Einsele, H., Facon, T. T. F., et al. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0203 · Cited by 108
Self-citationLacy, M. Q., & McCurdy, A. B. R. (2013) · Blood · doi:10.1182/blood-2013-05-484782 · Cited by 104
Lonial, S., Richardson, P. G., San Miguel, J., Sonneveld, P., Schuster, M. W., Bladé, J., Cavenagh, J., Rajkumar, S. V., Jakubowiak, A. J., Esseltine, D., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07321.x · Cited by 94
“…in the front-line and relapsed settings (Osman et al, 2001; Zangari et al, 2001, 2002; Rajkumar et al, 2002, 2006; Urbauer et al, 2002; Weber et al, 2003, 2007; Barlogie et al, 2006; Hussein et al, 2006; Knight et al, 2006; Niesvizky et al, 2006, 2008; Palumbo et al, 2006; Dimopoulos et al, 2007).”
BackgroundSelf-citationWeinstock, M. A., Aljawai, Y. M., Morgan, E. A., Laubach, J. P., Gannon, M., Roccaro, A. M., Varga, C., Mitsiades, C. S., Paba‐Prada, C. E., Schlossman, R. L., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13383 · Cited by 101
Lacy, M. Q., Mandrekar, S. J., Dispenzieri, A. A., Hayman, S. R., Kumar, S. K., Buadi, F. K., Dingli, D., Litzow, M. R., Wettstein, P. J., Padley, D. J., et al. (2009) · American Journal of Hematology · doi:10.1002/ajh.21560 · Cited by 92
Metadata
- Authors
- Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., Corso, A., Masliak, Z., Olesnyckyj, M., Yu, Z., Patin, J., Zeldis, J. B., & Knight, R. D.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- The Alfred Hospital (AU)
- Hôpital Purpan (FR)
- Peter MacCallum Cancer Centre (AU)
- Centre Hospitalier Universitaire de Nantes (FR)
- Gdańsk Medical University (PL)
- Hôpital Claude Huriez (FR)
- Sapienza University of Rome (IT)
- Policlinico San Matteo Fondazione (IT)
- Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine (UA)
- Celgene (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-22
- Volume
- 357
- Issue
- 21
- Pages
- 2123-2132
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1992538067
- Semantic Scholar
- 32cf6aa2c629905ca550153f79309e6594cf499b
- Cited by
- 1,450
- References
- 17
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 24 · 2023: 55 · 2022: 50 · 2021: 46 · 2020: 59 · 2019: 54 · 2018: 68 · 2017: 87 · 2016: 97 · 2015: 86 · 2014: 90 · 2013: 135 · 2012: 126
- FWCI
- 67.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- lenalidomide, dexamethasone, relapsed/refractory multiple myeloma, thalidomide analogues, time to progression, overall survival, complete response, neutropenia, venous thromboembolism, thrombocytopenia, combination chemotherapy, adverse events, immunomodulators, corticosteroids, treatment efficacy comparison
- MeSH terms
- Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Drug Therapy, Combination, Female, Glucocorticoids, Humans, Immunologic Factors, Male, Middle Aged, Multiple Myeloma, Recurrence, Thalidomide, Survival Analysis, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.